Primary and Metastatic Intracranial Ewing Sarcoma at Diagnosis: Retrospective International Study and Systematic Review

Lianne M. Haveman 1,*, Andreas Ranft 2, Henk van den Berg 3, Stephanie Klco-Brosius 2, Ruth Ladenstein 4, Michael Paulussen 5, Heribert Juergens 6, Uta Dirksen 2,† and Johannes H.M. Merks 1,‡

1 Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands; J.H.M.Merks@prinsesmaximacentrum.nl
2 Department of Pediatric Hematology and Oncology, University Children’s Hospital of Essen, Center of Pediatric Oncology, 45122 Essen, Germany; andreas.ranft@uk-essen.de (A.R.); Stephanie.Klco-Brosius@uk-essen.de (S.K.-B.); Uta.Dirksen@uk-essen.de (U.D.)
3 Department of Pediatric Oncology, Academic Medical Center, Emma Children’s Hospital, 1105 AZ Amsterdam, The Netherlands; h.vandenberg@amc.uva.nl
4 Children’s Cancer Research Institute, 1090 Vienna, Austria; ruth.ladenstein@ccri.at
5 Vestische Kinder- und Jugendklinik, Witten/Herdecke University, 45711 Datteln, Germany; M.Paulussen@kinderklinik-datteln.de
6 Department of Pediatric Hematology and Oncology, University Children’s Hospital, 48149 Muenster, Germany; jurgh@ukmuenster.de

* These authors contributed equally to this work.

Received: 29 May 2020; Accepted: 22 June 2020; Published: 24 June 2020

Abstract: Intracranial Ewing sarcoma (EwS) is rare and publications on primary or metastatic intracranial EwS are minimal. The aim of this study was to describe incidence, clinical behavior, treatment, and factors associated with outcome in patients with primary intracranial EwS or patients with a primary extracranial EwS and cerebral metastases at diagnosis. We reviewed all patients with primary or with metastatic intracranial EwS at diagnosis registered in the International Clinical Trial Euro-E.W.I.N.G.99 (EE99). In total, 17 of 1435 patients (1.2%) presented with primary intracranial EwS; 3 of them had metastatic disease. Four patients (0.3%) with primary extracranial EwS presented with intracranial metastatic lesions. The 3-year event-free survival (EFS) was 64% and overall survival (OS) was 70% in patients with a primary intracranial EwS. Local control in patients with primary intracranial EwS consisted of surgery (6%), radiotherapy (RT) (18%), or both modalities (76%). Univariate analysis showed that patients < 15 years of age had significantly better outcome (EFS: 72%; OS: 76%) compared to those aged above 15 years (EFS: 13%; OS: 25%). In conclusion, primary intracranial EwS and extracranial EwS with cerebral metastases at diagnosis is rare, yet survival is comparable with local and metastatic EwS elsewhere in the body. Age and stage of disease are important prognostic factors. Besides chemotherapeutic treatment, local control with surgical resection combined with RT is recommended whenever feasible.

Keywords: Ewing sarcoma; intracranial; metastatic; outcome

1. Introduction

According to the World Health Organization, the peripheral primitive neuroectodermal tumors, classic Ewing Sarcoma (EwS) and extraskeletal EwS, constitute the Ewing sarcoma family of tumors.

Cancers 2020, 12, 1675; doi:10.3390/cancers12061675 www.mdpi.com/journal/cancers
Primitive neuroectodermal tumors (PNETs) are composed of small undifferentiated embryonal-type round cells. For intracranial PNETs, a distinction is made between primitive neuroectodermal tumors of the central nervous system which includes medulloblastoma, supratentorial PNETs, and pineoblastoma, versus primitive neuroectodermal tumors of the peripheral nervous system, which encompasses Ewing sarcomas (EwSs), mainly arising from bone and soft tissue. The distinction between primitive neuroectodermal tumors of the central nervous system and peripheral primitive neuroectodermal tumors, or intracranial EwSs, is important regarding clinical behavior, treatment, and prognosis [1–3]. Although EwSs of the central nervous system may histologically appear quite similar to primitive neuroectodermal tumors of the central nervous system, EwSs show the characteristic chromosomal translocation t(11;22)(q24;12) in 85–90% of patients. This translocation results in fusion of the gene EWSR1 with the ETS family gene FLI1 (alias EWSR2). Less frequently, in about 10% of patients, EwSR1 fusions with other members of the ETS family occur, most commonly ERG. Occasionally, fusions between EwSR1 and non-ETS gene family members are seen [4,5]. These translocations are not found in primitive neuroectodermal tumors of the central nervous system. In addition, immunochemistry is used to distinguish intracranial EwSs from primitive neuroectodermal tumors of the central nervous system. Immunostaining for CD99, encoded by the MIC2 gene, is usually positive in EwSs of the central nervous system and negative in most primitive neuroectodermal tumors of the central nervous system. However, this antigen is not specific and is also expressed in some other central nervous system (CNS) tumors [5,6].

In children, the incidence of EwS is about 4.5 cases/million a year, with a peak incidence of 11 cases/million at the age of 12 years [7]. Primary intracranial EwS is extremely rare and the number of publications on primary intracranial EwS or patients with extracranial EwS with cerebral metastases is minimal; nearly all are confined to single case reports. Adverse prognostic factors in EwS are age > 14 years, initial tumor volume > 200 mL, poor histological response to induction chemotherapy, male gender, high lactate dehydrogenase (LDH) at diagnosis, and metastatic disease [8,9]. Whether these factors are relevant in intracranial EwS is unknown. To sort this out, we reviewed all patients with primary intracranial EwS and patients with extracranial EwS and intracranial metastatic disease at diagnosis treated according to the International Clinical Trial Euro-E.W.I.N.G. 99 (EE99) protocol and included in the GPOH-EE99 registry [10]. The aim of this study was to describe the incidence, clinical behavior, and treatment received, and analyze the factors associated with outcome in patients with primary intracranial EwS and patients with primary extracranial EwS and cerebral metastases at diagnosis. In addition, we performed a literature review on previously published reports on this topic. Therewith, this paper encompasses the largest series on intracranial EwS published in the literature to date.

2. Results

2.1. Patient Characteristics and Treatment

In total, 1435 patients were included in the EE99 database during a 10-year period. The median follow-up was 4.2 years (range 0.87–12.68). In total, 21 patients (=1.5%) presented with a primary or metastatic intracranial EwS. Seventeen patients (=1.2%) presented with primary intracranial EwS. Three of these 17 patients, in addition to their intracranial primary, had metastatic lesions in the CNS. Four out of 21 patients (=0.3%) were diagnosed with an extracranial primary EwS elsewhere in the body and had intracerebral metastatic lesions. In Table 2, the characteristics and treatment modalities of these patients are shown. In seven patients, all with primary intracranial EwS, cerebrospinal fluid (CSF) puncture was performed; malignant cells were found in two patients.
Table 1. Baseline characteristics and treatment modalities of included patients with primary and metastatic intracranial Ewing sarcoma.

| Pat. Nr. | Age (Years) | Sex (M/F) | Tumor Volume >200 mL | Meta- Stases (M): CNS, B, BM, P | Origin | Cranial Bone Involvement (yes/no) | -Histopathology -Immunohistochemistry -Translocation | Local Therapy (SR and/or RT) | Radical/ Marginal/ Intra-Lesional Surgery | Good (<10% Vital Cells) or Poor HR | Chemo-Therapy Courses | Pt. or LR | Patient Status (Dead/ Alive) | OS (Year) | EFS (Year) |
|----------|-------------|-----------|----------------------|---------------------------------|--------|-----------------------------------|-----------------------------------------------|-----------------------------|--------------------------------------|----------------------------------|-----------------------------|--------|-----------------------------|----------|----------|
| 1        | 11.08       | F         | No (117 mL)          | No                              | Frontal lobe                     | yes                               | Neurodiff. PAS+, CD99+, S100+, NSE+ Desmin+ synaptophys+ | SR and RT marginal           | NR                                   | 6x VIDE 8x VAI alive | alive         | 8.45  | 8.45                         |
| 2        | 53.76       | M         | No                   | Yes: CNS, L+                    | Temporal                         | no                                | Neurodiff. S100+                     | Upfront resection + RT Intra-lesional UR | 6x VIDE 7x VAC Pr died | 1.26  | 1.02                         |
| 3        | 12.78       | M         | No                   | No                              | Posterior cranial fossa          | yes                               | Neurodiff. CD99+, S100= Mol: t(11,22) neg | SR and RT Intra-lesional NR | 6x VIDE 1x VAI 7x VAC died | 5.90  | 3.35                         |
| 4        | 19.72       | F         | No                   | No                              | Skull base left/ intra-cranial   | yes                               | Undiff. RT                           | 6x VIDE 7x VAC alive | 8.79  | 7.93                         |
| 5        | 30.36       | F         | Yes                  | No                              | Frontodural                      | yes                               | Neuroiff. Pas+, mic+, sl100+, vimentin+ | SR and RT Intra-lesional Poor HR | 6x VIDE 8x VAI | LR died | 3.16  | 1.78                         |
| 6        | 7.44        | M         | No (176 mL)          | No                              | Frontobasal                      | no                                | Neuroiff.                        | 6x VIDE 6x VAI 2x VAC alive | 11.18 | 11.18                        |
| 7        | 9.63        | M         | Yes (236 mL)         | Yes: CNS, L+                    | Parietal, M in cere-bellum       | yes                               | Neuroiff. Mol: t(11,22) neg; 22q12 | RT                           | 6x VIDE 3x other * 1x HD alive | 3.97  | 3.97                         |
| 8        | 6.95        | M         | No                   | No L-                           | Fronto-parietal; epidural and dural | yes                               | Neuroiff. Pas+, mic+, nse= negatif, sl10? Vimentin+ | -Upfront resection -pre-op. RT +SR of resttumor -intra-lesional -radical -UR -Good HR | 6x VIDE 1x VAI 7x VAC alive | 10.4  | 10.4                         |
| 9        | 15.71       | F         | No                   | No                              | Para-meningeal, area middle cranial fossa | yes                              | Undiff.                        | SR and RT marginal NR | 6x VIDE 1x VAI 7x VAC | LR died | 1.48  | 1.43                         |
| 10       | 6.08        | F         | No                   | No                              | Frontal lobe                     | yes                               | Neuroiff. MIE2+, S100+ NSE+ vimentin+ | SR radical Good HR | 6x VIDE 8x VAI | alive         | 7.86  | 7.86                         |
| 11       | 10.48       | M         | No (67 mL)           | No                              | Temporal                         | yes                               | Neuroiff. Mol: t(11,22) pos       | SR and RT radical NR | 6x VIDE 1x VAI 7x VAC | alive         | 4.29  | 4.29                         |
Table 2. Baseline characteristics and treatment modalities of included patients with primary and metastatic intracranial Ewing sarcoma.

| Pat. Nr. | Age (Years) | Sex (M/F) | Tumor Volume >200 mL | Meta- Stases (M): CNS, B, BM, P | Origin | Cranial Bone Involvement (yes/no) | -Histopathology -Immunohistochemistry -Translocation | Local Therapy (SR and/or RT) | Radical/ Marginal/ Intra-Lesional Surgery | Good (<10% Vital Cells) or Poor HR | Chemo-Therapy Courses | Pt. or LR | Patient Status (Dead/ Alive) | OS (Year) | EFS (Year) |
|----------|-------------|-----------|----------------------|---------------------------------|--------|-----------------------------------|---------------------------------------|--------------------------|-----------------------------------|-----------------------------------|--------------------------|--------|-----------------------------|----------|----------|
| 12       | 69.34       | M         | No                   | No                              | Parieto- occipital              | no      | Neurodiff: CD99+, NSE+ vimentin+ Mol: t(11,22) pos | Upfront resection + RT | marginal                           | UR                               | 6x VIDE 7x VAC                  | LR died | 1.26 1.26                  |
| 13       | 10.30       | F         | No (23 mL)           | No                              | Fossa posterior                 | no      | Undiff: PAS+, CD99+, S100+ Vimentin+ desmin− Mol: no t(11,22) but breakage of EwS gene on 22 | Upfront resection + RT | Intra-lesional                      | UR                               | 6x VIDE 8x VAI                  | alive    | 10.52 10.52               |
| 14       | 3.58        | F         | No (86 mL)           | No L−                           | Temporal                         | yes     | Neurodiff: PAS+, CD99+, NSE+ vimentin+ desmin− Mol: (t11,22) neg EwS/Fli 7/6 (type 2) | SR and RT               | Intra-lesional                     | NR                               | 6x VIDE 8x VAC                  | alive    | 2.84 2.84                  |
| 15       | 4.36        | F         | No (22 mL)           | No L−                           | Parietal                         | yes     | Neurodiff: PAS+, CD99+, S100+, desmin− Mol: chr22q12 | Upfront resection + RT | marginal                           | UR                               | 6x VIDE + other** 8x VAC        | alive    | 4.53 4.53                  |
| 16       | 33.46       | F         | ?                    | No                              | Occipital with intra-cerebral lesions | no     | Neurodiff: PAS+ CD99+, S100+ NSE+ desmin− | Upfront resection + RT | radical                            | UR                               | 6x VIDE 8x VAI                  | alive    | 12.68 12.68               |
| 17       | 11.85       | M         | Yes (291 mL)         | No                              | Parietal + os sacrum *** yes    | CD99+ S100− desmin− Mol: Eos/Fli 7/6 type I; t(11,22) | RT                        | -                                   | -                                | 6x VIDE 8x VAI 1x HD            | Pr died  | 1.08 0.81                  |

Patients with extracranial EwS and intracerebral metastases at diagnosis

| 18       | 16.55       | M         | Yes (628 mL)         | Yes: CNS, B, BM                  | Tibia; multifocal skull, intra-cerebral, and meningeal | yes     | Undiff: PAS− CD99+ | RT | - | 6x VIDE 1x VAI 1x HD | Pr died 1.26 1.05 |
| 19       | 14.12       | F         | Yes                  | Yes: CNS, B, BM                  | costal; frontal epidural | yes     | Mol: t(11,22) transcript 22q12 | RT | - | 6x VIDE 1x VAI 1x HD | alive 9.70 9.70 |
| 20       | 53.13       | F         | Yes                  | Yes: CNS, B, BM                  | Sacrum; fossa posterior | yes     | Undiff: No t(11,22) or t(21,22) | no | - | 4x VIDE                  | Pr died 0.87 0.36 |
| 21       | 16.21       | M         | No (137 mL)          | Yes: CNS                          | os ilium; occipital         | yes     | Neurodiff: Mol: t(11,22) pos | RT | - | 6x VIDE 8x VAI 1x HD | LR died 2.52 1.92 |

CNS = central nervous system, RT = radiotherapy, SR = surgical resection, EFS = event-free survival, OS = overall survival, CNS = central nervous system, P = pulmonary, B = bone, BM = bone marrow, NR = not reported, UR = Upfront resection, HR = histological response, VIDE = vincristine, ifosfamide, doxorubicin, and etoposide, VAI = vincristine, actinomycin D, ifosfamide; VAC = vincristine, actinomycin D, cyclophosphamide; HD = high dose chemotherapy; Pr = progression under treatment; LR = local recurrence. * = three courses of vinblastine combined with intrathecal etoposide; ** = intrathecal topotecan; *** large intracerebral lesion, small lesion sacrum, unknown, which lesion was the primary lesion.
The median age of patients with primary intracranial EwS at diagnosis was 11.1 years (range 3.6–69.3 years); 12/17 (71%) of patients were younger than 18 years. The median age of the 4 patients who presented with intracranial metastatic disease was 16.4 years (range 14.1–53.1 years). In 16/17 patients with primary intracranial EwS, the tumor volume at diagnosis was known. In 13/16 patients, the tumor volume was below 200 mL. In 3 of the 4 intracranial metastatic patients, the primary tumor volume was above 200 mL.

In eight patients, the clinical symptoms at diagnosis could be extracted from physician’s letters. Clinical symptoms were rather diverse and consisted of headache and double vision (patient number (pat.nr.) 1); epileptic seizures and behavior change (pat.nr. 2); headache and hyposmia (pat.nr. 5); headache and swelling (pat.nr. 8); swelling without further symptoms (pat.nr. 10, pat.nr. 16); headache and papilledema (pat.nr. 12); and fever, general malaise, and swelling (pat.nr. 21; localization iliac bone with occipital brain metastasis). Sixteen of 21 patients had cranial bone involvement.

All patients received induction chemotherapy with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) according to the EE99 protocol. Two patients with primary intracranial EwS underwent high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (aSCT) in the consolidation phase; one of them had proven EwS cells in the CSF at diagnosis. Before HDCT, this patient received three courses of vinblastine combined with intrathecal etoposide (pat.nr. 7). The other patient (pat.nr. 17), who also had a (smaller) lesion in the sacrum, received HDCT after eight courses with vincristine, actinomycine D, and ifosfamide (VAI). According to EE99, patients with metastatic disease were to receive HDCT followed by aSCT.

However, one patient with extracranial EwS and metastatic intracerebral lesions showed progressive disease after the fourth VIDE course and antitumor treatment was stopped. One patient with primary intracranial EwS (pat.nr. 15) received intrathecal topotecan, although this patient had a negative CSF puncture.

In four of the five patients with a CNS primary without bone involvement, upfront surgery was performed. In two additional patients, upfront surgery was done, both because of symptoms due to increased intracranial pressure. In all other patients, local therapy was performed after induction chemotherapy. In 13/17 (76%) of the patients with primary intracranial EwS, local therapy consisted of both surgery and radiotherapy (RT). In 3/17 patients (18%), definitive RT was given; two of these patients had intracerebral metastases. In only 1/17 patients (6%) who presented with primary EwS of the brain, surgery without additional RT was performed. In this patient, surgery was radical and there was a good histopathological response. Three of the four patients with extracranial EwS with metastatic intracranial disease received definitive RT; the fourth patient showed progression of disease before local therapy could be started.

For 13/14 patients who underwent surgery, data on resection margins were known. In 3/13 patients, a radical resection was achieved; in 4/13, a marginal resection; and in 6/13, the resection was intralicesional. Histological response was reported in only four patients; two had a poor histological response.

During follow-up, 3 of 17 patients with primary intracranial EwS (17.6%) had a local recurrence (LR) after initial complete remission; intracranial relapse occurred in one of the four patients with extracranial EwS and cerebral metastases. Two of the 17 patients (11.7%) with primary intracranial EwS showed progressive disease while on therapy, as did 2/4 patients with intracerebral metastatic disease at diagnosis.

2.2. Outcome and Prognostic Factors

After a median follow-up time of 4.2 years, the 3-year event-free survival (EFS) for the total cohort was 0.57 (standard error (SE) = 0.11) and 3-year overall survival (OS) was 0.62 (SE = 0.11). In the cohort of patients with primary intracranial EwS, 11 patients were free of disease (65%); 3-year EFS was 0.64 (SE = 0.12) (Figure 1a) and OS was 0.70 (SE = 0.11) (Figure 1b). The three patients with primary intracranial EwS and CNS metastases at diagnosis did worse; only one was alive after 9.7 years of follow-up. For patients with extracranial EwS with intracerebral metastatic disease at diagnosis, only
one patient was alive after 9.3 years. All patients with LR ($n = 4$) and the patients with progressive disease under therapy ($n = 4$) died. Univariate analysis was performed on patients with primary intracranial EwS in order to determine the influence of local treatment modalities on survival.

![Event Free Survival](image1)
![Overall Survival](image2)

**Figure 1.** (a) Event-free survival (EFS) and (b) overall survival (OS) in patients with primary intracranial EwS ($n = 17$) and extracranial EwS patients with intracerebral metastases at diagnosis ($n = 4$).

However, numbers in the subgroups were not equally distributed. Due to small numbers, no statistical analysis was performed; however, a descriptive analysis of the relation between therapy and survival showed no difference in survival between treatment with RT alone or combined surgery and RT. Three patients (18%) received RT alone; two of them had brain metastases. Two patients were alive after 3.8 and 4.0 years of the follow-up period. One patient with CNS metastases died after 1.1 years of treatment. Thirteen patients (76%) received combined local treatment. Eight patients were alive after a median follow-up time of 8.1 years. The single patient treated by surgery only was alive after 7.86 years of follow-up. This patient had a surgical resection with negative margins and a good histological response to chemotherapy.

In 12/17 patients, the resection margins were known. In the patients with surgical resection and negative margins ($n = 2$), no events occurred. In both the group with marginal resection ($n = 4$) and the group of patients with an intraslesional resection ($n = 6$), all received RT; half of the patients were alive at the end of the follow-up period. Studying the patients with primary intracranial EwS, no difference in EFS could be found between the 12 patients with involvement of cranial bones (3-year EFS 0.66 (SE = 0.14)) compared to the 5 patients without bone involvement (EFS 0.60 (SE = 0.14)). The 3-year OS was 0.74 (SE = 0.13) and 0.60 (SE = 0.22), respectively ($p = 0.80$). Patients with an age below 15 years ($n = 11$) had a 3-year EFS of 0.81 (SE = 0.12) compared to an EFS of 0.17 (SE = 0.15) for patients above 15 years ($n = 6$) years of age ($p = 0.015$). The 3-year OS was 0.76 (SE = 0.16) compared to an OS of 0.33 (SE = 0.19), respectively ($p = 0.05$).

Only one of the three patients with a tumor volume $>$200 mL was alive after 4 years of follow-up (EFS 0.33; OS 0.33). In the 13 patients with a tumor volume $<$200 mL, EFS was 0.68 and OS 0.66, respectively. Due to the limited number of patients with a large tumor volume, statistical analysis was not possible.

A multivariate analysis of prognostic factors was not performed due to the limited sample size.

### 2.3. Literature Review

The literature search revealed a total of 920 articles. The process of the publication retrieval and the inclusion and exclusion of the studies was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and is shown in Figure 2 [11]. By reviewing the titles and abstracts, seven studies on primary intracranial Ewing sarcoma describing three or more cases were considered [12–18]. No studies with three or more patients with primary extracranial EwS and intracerebral metastatic disease at diagnosis could be included. Details of the
seven included studies describing patients with primary intracranial EwS are described in Table 3. Due to heterogeneous studies, a meta-analysis of the studies was not possible.

In conclusion, the 7 selected studies were very dissimilar and included only small patient numbers in the range of 3–14 patients. Only two studies [13,15] included patients treated according a uniform chemotherapy protocol, with respectively four and seven patients. Important data on local treatment [14–16,18] and/or outcome [17,18] were missing in most of the studies. In general, the authors suggest that long-term survival may best be achieved if an Ewing-based chemotherapy regimen is given, and (radical) surgery is combined with RT [12–14].
Table 3. Characteristics and treatment modalities of studies with case series of three or more patients with primary intracranial Ewing sarcoma.

| Author          | No. of Subjects | No. of Patients with Metastatic Disease | Mean Age (Range) in Years | Mean Follow-up (range) in Months | Uniform Chemo-Therapy Protocol | No. of Patients Treated with CT | No. of Patients with SR | No. of Patients with Radical SR | No. of Patients with Marginal SR | No. of Patients with RT alone | No. of Patients with SR and RT | LR Rate (%) | Survival         |
|-----------------|-----------------|----------------------------------------|---------------------------|----------------------------------|--------------------------------|-------------------------------|-----------------------|-------------------------------|----------------------------------|-----------------------------|-------------------------------|-----------------|-----------------|
| Chen et al. [12] | 14              | 3                                      | 14.1 (1–43)               | 30.1 (6–84)                      | No                            | 10                            | 14                    | 7 (50%)                       | 7 (50%)                          | -                          | 9                             | 71.4           | 5-year OS 19%   |
| Colak et al. [13]| 4               | -                                      | 13.8 (6–26)               | 32.0 (11–69)                     | Yes                           | 4                             | 4                     | 3 (75%)                       | 1                               | 3                          | NR                            | 100%           | 25% died (36 months) 75% alive: mean 32 months (11–69) |
| Yang et al. [14] | 4               | -                                      | 10 (5–16)                 | 49.5 (12–126)                    | No                            | 4                             | 4                     | NR                           | NR                              | -                          | 4                             | 25%            | 57% died, mean 33.2 months PFS n = 3: 23.3 months |
| Singh et al. [15]| 7               | -                                      | 13 (7–21)                 | 26.9 (12–48)                     | Yes                           | 2                             | (+1 pat. after LR) | 7                            | NR                              | -                          | 4                             | 14%            | 57% died, mean 33.2 months PFS n = 3: 23.3 months |
| Jing et al. [16] | 8               | 3                                      | 15 (7–23)                 | NR                               | NR                            | NR                            | 8                     | NR                           | NR                              | -                          | 8                             | NR             | 0%              |
| Ke et al. [17]   | 3               | -                                      | 19.3 (15–28)              | NR                               | Yes                           | 3                             | 3                     | 2                            | 1                               | -                          | 3                             | 66.7%         | n = 1: >6 years n = 2 with LR: lost to f.u. |
| Vanden Heuvel et al. [18]| 3 | -                                      | 21.8 (2.4–61)             | NR                               | No                            | 2                             | 3                     | NR                           | NR                              | -                          | 1                             | -              | n = 1: >5 years n = 1: >18 months n = 1: lost to f.u |

No. = number, SR = surgical resection, RT = radiotherapy; LR = local recurrence; EFS = event-free survival, OS = overall survival; PFS = progression-free survival; NR = not reported, P = progression.
3. Discussion

Intracranial EwS is rare, and meticulous delineation from other intracranial primitive neuroectodermal tumors has to be assured. Of all patients included in the EE99-trial, 17 patients (1.2%) presented with a primary intracranial EwS with involvement of the dura or cerebral parenchyma. Three of them in addition had CNS metastases at diagnosis. This is in line with reported incidences of primary intracranial EwS of 1–6% in earlier studies [19,20]. In our study, only four patients (0.3%) with a primary extracranial EwS presented with intracerebral metastatic lesions at diagnosis. This is the largest cohort treated according to a uniform chemotherapeutic regimen to date. In the literature, no other cohort studies could be found describing patients with extracranial EwS and intracerebral metastases at diagnosis. However, intracranial metastases at a later stage of the disease, as a result of hematogenous metastatic spread, is more frequently reported in the range of 2–10% [21–23].

In patients with intracranial EwS, the disease often originates from the cranial bones. Usually, this also means involvement of the meninges and the epidural space [13,24,25]. EwSs that do not originate from the cranial bones are described to a lesser extent. Recently, however, a patient with a sellar/suprasellar mass with intraventricular extension has been described [26].

In a previous report, we described 51 patients with EwS of the head and neck region included in the EE99-trial [27]. In this study, 23 of the 51 of the patients were diagnosed with a primary EwS of the skull. In the present study, only patients with lesions within the cerebrum or entering the cerebrum or infiltration of the dura were included.

Treatment options in patients with cerebral EwS are identical to EwS elsewhere in the body and include chemotherapy, surgery, and/or RT. Patients who underwent surgery and/or RT combined with chemotherapy had better outcomes as compared to patients who did not have adjuvant chemotherapy [12–14,25]. The efficacy of chemotherapy could be limited by the ability of the drugs to cross the blood–brain barrier (BBB). In the EE99 protocol, patients are all treated with induction chemotherapy with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE). Ifosfamide is assumed to penetrate through the blood–brain barrier due to its lipid solubility, small molecular size, and minimal binding to plasma and tissue proteins. This is confirmed in several studies; however, interpatient variability of CFS/plasma ratios is described, which may explain differences in efficacy and toxicity among patients [28,29]. Limited data are available about the penetration of etoposide across the BBB. For etoposide, the tissue to blood ratios seem low [30,31]. The penetration for doxorubicin and vincristine into the brain parenchyma is also low [32,33]. In the presented study cohort, one patient received intrathecal topotecan in addition to the VIDE chemotherapy backbone, although the CSF at diagnosis was negative for malignant cells in this case. Another patient received three courses of vinblastine combined with intrathecal etoposide, scheduled shortly before high-dose chemotherapy. Both patients were alive at follow-up. The value of intrathecal chemotherapy in EwS of the CNS is unknown; however, the National Cancer Institute as part of the Intergroup Ewing’s Sarcoma Study Committee treated a group of 93 EwS patients with prophylactic CNS irradiation and intrathecal methotrexate. It was concluded that the risk of CNS involvement in patients with EwS was not affected [23].

The survival rate in EwS has improved due to the implementation of multi-modality treatment. OS is about 70% in patients with localized disease; however, OS is lower than 30% in patients with metastatic disease [8,34]. In this study, the 3-year EFS was 64% and OS was 70% in patients with primary intracranial EwS. This is in line with the survival rate of localized EwS elsewhere in the body. Consistent with earlier studies, in our study, patient age below 15 years and localized disease seemed to be good prognostic factors [8,9]. Involvement of bone structures did not seem to affect outcome. Patients with metastatic disease had a 3-year EFS and OS of 28%, comparable with results reported earlier [25].

In general, treatment of EwS includes at least marginal surgical resection. Surgery has to be combined with RT in the case of narrow margins and/or poor histological response. Surgical resection with negative margins in the case of intracranial tumors is very difficult to achieve in most of the
patients; therefore, RT should be added. In order to limit unacceptable morbidity from surgery, a less invasive resection in tumors that involve the skull base and vascular regions, such as the cavernous sinus, may be accepted [35]. In patients with EwS of the head and neck region, no difference could be found in the outcome between patients treated with surgery, RT, or combined surgery and RT [27]. In the present study, 76% of the patients received combined modality local treatment. There seems to be no difference in outcome between local treatment groups, but definitive conclusions cannot be drawn due to the small patient numbers. Limitations of this study include also its retrospective nature. However, based on the available data, a treatment composed of chemotherapy, surgery combined with RT is advised according to the general guidelines for treatment of EwS. However, in patients with intracranial EwS, radical surgery will not be feasible in a considerable proportion of patients. In these patients, and in patients with metastatic disease, definitive RT should be given. Stereotactic radiosurgery seems a promising treatment modality, but no experience is reported in intracranial EwS.

4. Materials and Methods

4.1. Study Population

We analyzed data from Ewing sarcoma patients, included in the German Society for Pediatric Oncology and Hematology (GPOH) database of the EE99 trial between September 1999 and September 2009 [10]. Patients with primary intracranial EwS or patients with primary extracranial EwS and cerebral metastases at diagnosis were included in the study. If available, detailed information was extracted from medical letters and reports or patient files. Patients were included if the lesions were located within the cerebrum or entering the cerebrum, i.e., with infiltration of the dura. Patients with lesions outside the cranial bones were only included if there was also an intracerebral component with involvement of the cerebral parenchyma. Patients were excluded for this study if there was an intracranial lesion without involvement of the dura and/or cerebral parenchyma. Primary EwS was confirmed by histopathology and molecular diagnostics in all patients. Patients less than 50 years of age were eligible and included in the EE99 study. Patients older than 50 years and patients who did not meet inclusion criteria or fulfilled exclusion criteria were included as registry patients. Informed consent was obtained from all patients and/or legal guardians. The protocol (ClinicalTrials.gov identifier: NCT00020566) was reviewed and approved by the appropriate institutional review boards, ethical committees, and legal authorities. Informed consent was obtained from all patients and/or legal guardians according to the Declaration of Helsinki and national guidelines.

4.2. Treatment

EE99 induction chemotherapy consisted of 6 courses of VIDE. Local control was generally carried out after the sixth course of induction chemotherapy, with a preference for surgical intervention with or without additional RT. Following local therapy, risk-adapted chemotherapy was administered as part of the randomized study questions [10]. After surgery, the histopathological response was determined. A good histological response was defined as less than 10% of viable tumor cells in the specimen.

4.3. Survival

Event-free survival (EFS) was defined as the interval between the date of diagnosis and the date of the first event. In the absence of events, patients were censored on the date of their most recent consultation. An event was defined as progressive disease, relapsed disease (local or metastatic), secondary malignancy, or death from any cause. Overall survival (OS) was defined as the time from diagnosis until death from any cause.

4.4. Statistical Analyses

Statistical analyses were performed with SPSS statistics 22 (IBM Corporation, Armonk, NY, USA) and SAS 9.2 (SAS Institute, Cary, NC, USA) software packages. Event-free survival (EFS) and overall
survival (OS) were calculated using the Kaplan–Meier method. Surviving patients were censored at the date of last contact. Univariate comparisons were estimated using the log-rank test.

4.5. Literature Review

A PubMed database search for primary intracranial Ewing sarcoma and extracranial EwS with intracranial metastases was performed. We used a Medline search strategy with words from the title or the abstract:

#1 for Ewing sarcoma: Ewing OR ewings OR ewing* OR ewing sarcoma OR peripheral neuroectodermal tumor OR peripheral neuroectodermal tumour OR peripheral neuroectodermal tumors OR peripheral neuroectodermal tumors OR primitive neuroectodermal tumor OR primitive neuroectodermal tumors OR primitive neuroectodermal tumors OR primitive Neuroepithelial Tumor OR Primitive Neuroepithelial Tumors OR Primitive Neuroepithelial Tumor OR Primitive Neuroepithelial Tumors OR Primitive Neuroepithelial Neoplasm OR Primitive Neuroepithelial Neoplasms OR PNET OR PNETs OR askin.

#2 for primary intracranial or intracranial metastases: intracranial OR cerebral OR CNS OR dural

A search until 31 December 2019 was conducted. For this study, searches were limited to articles published in English and only studies describing 3 or more patients were included. To identify additional eligible studies, reference lists of included studies were screened.

5. Conclusions

Primary and metastatic intracranial EwS at diagnosis is very rare. This study shows that survival in both primary intracranial and metastatic disease is comparable to local and metastatic EwS elsewhere in the body. Known prognostic factors in patients with EwS as age, disease stage at diagnosis, and also tumor volume seem to also hold for patients with intracranial EwS. In general, patients with intracranial EwS should, if the clinical symptoms permit, be treated according to a standard EwS treatment, where induction chemotherapy is followed by local therapy and subsequently maintenance chemotherapy. For local control, surgery combined with RT is recommended. However, no differences in survival could be detected comparing surgical outcome in respect to the achieved margins. Patients that received definitive RT showed comparable survival and is indicated in patients where surgery is not possible or in patients with metastatic disease.

Author Contributions: Conception and design, L.M.H., H.v.d.B., H.J., U.D., J.H.M.M.; Administrative support, U.D.; Provision of study materials or patients, R.L., A.R., M.P., H.v.d.B.; Collection and assembly of data, L.M.H., A.R., R.L., H.v.d.B., U.D.; Data analysis and interpretation: L.M.H., A.R., J.H.M.M.; Manuscript writing, L.M.H., H.M., H.v.d.B., U.D., S.K.-B.; Final approval of manuscript, L.M.H., A.R., H.v.d.B., S.K.-B., R.L., M.P., H.J., U.D. and J.H.M.M. All authors have read and agreed to the published version of the manuscript.

Funding: This work has been supported by the Deutsche Krebshilfe (DKH) 108128, and EEC [602856-2].

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Theeler, B.J.; Keylock, J.; Yoest, S.; Forouhar, M. Ewing’s sarcoma family tumors mimicking primary central nervous system neoplasms. J. Neurol. Sci. 2009, 284, 186–189. [CrossRef] [PubMed]
2. Kumar, V.; Singh, A.; Sharma, V.; Kumar, M. Primary intracranial dural-based Ewing sarcoma/ peripheral primitive neuroectodermal tumor mimicking a meningioma: A rare tumor with review of literature. Asian J. Neurosurg. 2017, 12, 351–357. [CrossRef] [PubMed]
3. Kazmi, S.A.; Perry, A.; Pressey, J.G.; Wellons, J.C.; Hammers, Y.; Palmer, C.A. Primary Ewing sarcoma of the brain: A case report and literature review. Diagn. Mol. Pathol. 2007, 16, 108–111. [CrossRef] [PubMed]
4. De Alava, E. Ewing Sarcoma, an Update on Molecular Pathology with Therapeutic Implications. Surg. Pathol. Clin. 2017, 10, 575–585. [CrossRef] [PubMed]
5. Grünewald, T.G.P.; Cidre-Aranaz, F.; Surdez, D.; Tomazou, E.M.; de Alava, E.; Kovar, H.; Sorensen, P.H.; Delattre, O.; Dirksen, U. Ewing sarcoma. Nat. Rev. Dis. Primers. 2018, 4, 5.
6. Ladanyi, M.; Lewis, R.; Garin-Chesa, P.; Rettig, W.J.; Huvos, A.G.; Healey, J.H.; Jhanwar, S.C. EWS rearrangement in Ewing’s sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression. *Dian. Mol. Pathol.* **1993**, 2, 141–146.

7. Van den Berg, H.; Kroon, H.M.; Slaar, A.; Hogendoorn, P. Incidence of biopsy-proven bone tumors in children: A report based on the Dutch pathology registration “PALGA”. *J. Pediatr. Orthop.* **2008**, 28, 29–35. [CrossRef]

8. Ladenstein, R.; Pöttschger, U.; Le Deley, M.C.; Whelan, J.; Paulussen, M.; Oberlin, O.; van den Berg, H.; Dirksen, U.; Hjorth, L.; Michon, J.; et al. Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. *J. Clin. Oncol.* **2010**, 10, 3284–3291. [CrossRef]

9. Bacci, G.; Longhi, A.; Ferrari, S.; Mercuri, M.; Versari, M.; Bertoni, F. Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: An analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. *Acta Oncol.* **2006**, 45, 469–475. [CrossRef]

10. Juergens, C.; Weston, C.; Lewis, I.; Whelan, J.; Paulussen, M.; Oberlin, O.; Michon, J.; Zoubek, A.; Juergens, H.; Craft, A. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.L.N.G. 99 clinical trial. *Pediatr. Blood Cancer* **2006**, 47, 22–29. [CrossRef]

11. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration (Version 2). *BMJ* **2009**, 21, 339-b2700. [CrossRef]

12. Chen, J.; Jiang, Q.; Zhang, Y.; Yu, Y.; Zheng, Y.; Chen, J.; Zhao, Y.; Miao, Z.; Fan, F.; Wang, Y. Clinical Features and Long-Term Outcome of Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumors: 14 Cases from a Single Institution. *World Neurosurg.* **2019**, 122, e1606–e1614. [CrossRef] [PubMed]

13. Colak, A.; Berker, M.; Ozcan, O.E.; Erbengi, A. CNS involvement in Ewing’s sarcoma. A report of 12 cases. *Acta. Neurochir.* **1991**, 113, 48–51. [CrossRef] [PubMed]

14. Yang, M.J.; Whelan, R.; Madden, J.; Mulcahy Levy, J.M.; Kleinschmidt-DeMasters, B.K.; Hankinson, T.C.; Foreman, N.K.; Handler, M.H. Intracranial Ewing sarcoma: Four pediatric examples. *Childs Nerv. Syst.* **2018**, 34, 441–448. [CrossRef] [PubMed]

15. Singh, A.K.; Srivastava, A.K.; Pal, L.; Sardhara, J.; Yadav, R.; Singh, S.; Bhaisora, K.S.; Das, K.K.; Mehrotra, A.; Sahu, R.N.; et al. Extraosseous Primary Intracranial Ewing Sarcoma/peripheral Primitive Neuroectodermal Tumor: Series of Seven Cases and Review of Literature. *Asian J. Neurosurg.* **2018**, 13, 288–296. [PubMed]

16. Jing, Z.; Wen-Yi, L.; Jian-Li, L.; Jun-Lin, Z.; Chi, D. The imaging features of meningeal Ewing sarcoma/peripheral primitive neuroectodermal tumours (pPNETs). *Br. J. Radiol.* **2014**, 87, 1041. [CrossRef]

17. Ke, C.; Duan, Q.; Yang, H.; Zhu, F.; Yan, M.; Xu, S.P.; Zhou, S.; Wan, F.; Shu, K.; Lei, T.; et al. Meningeal Ewing Sarcoma/Peripheral PNET: Clinicopathological, Immunohistochemical and FISH study of four cases. *Neuropathology* **2017**, 37, 35–44. [CrossRef]

18. VandenHeuvel, K.A.; Al-Rohil, R.N.; Stevenson, M.E.; Qian, J.; Gross, N.L.; McNall-Knapp, R.; Li, S.; Warthow, E.P.; Mierau, G.W.; Fung, K.M. Primary intracranial Ewing’s sarcoma with unusual features. *Int. J. Clin. Exp. Pathol.* **2015**, 8, 260–274.

19. Li, M.; Hoschar, A.P.; Budd, G.T.; Chao, S.T.; Scharpf, J. Primary Ewing’s sarcoma of the ethmoid sinus with intracranial and orbital extension: Case report and literature review. *Am. J. Otolarangol.* **2013**, 34, 563–568. [CrossRef]

20. Bhattacharjee, S.; Venkata, S.R.; Uppin, M.S. Skull and spinal Ewing’s sarcoma in children: An institutional study. *J. Pediatr. Neurosci.* **2018**, 13, 392–397. [CrossRef]

21. Shuper, A.; Cohen, I.J.; Mor, C.; Ash, S.; Kornreich, L.; Zaizov, R. Metastatic brain involvement in Ewing family of tumors in children. *Neurology* **1998**, 51, 1336–1338. [CrossRef] [PubMed]

22. Parasuraman, S.; Langston, J.; Rao, B.N.; Poquette, C.A.; Jenkins, J.J.; Merchant, T.; Cain, A.; Pratt, C.B.; Pappo, A.S. Brain metastases in pediatric Ewing sarcoma and rhabdomyosarcoma: The St. Jude Children’s Research Hospital experience. *J. Pediatr. Hematol. Oncol.* **1999**, 21, 370–377. [CrossRef] [PubMed]

23. Trigg, M.E.; Glaubiger, D.; Nesbit, M.E., Jr. The frequency of isolated CNS involvement in Ewing’s sarcoma. *Cancer* **1982**, 49, 2404–2409. [CrossRef]

24. Ibrahim, G.M.; Fallah, A.; Shahideh, M.; Tabori, U.; Rutka, J.T. Primary Ewing’s sarcoma affecting the central nervous system: A review and proposed prognostic considerations. *J. Clin. Neurosci.* **2012**, 19, 203–209. [CrossRef]
25. Cherif El Asri, A.; Benzagmout, M.; Chakour, K.; Chaoui, M.F.; Laaguili, J.; Chahdi, H.; Gazzaz, M.; El Mostarchid, B. Primary Intracranial ppNET/Ewing Sarcoma: Diagnosis, Management, and Prognostic Factors Dilemma-A Systematic Review of the Literature. *World Neurosurg.* 2018, 115, 346–356. [CrossRef] [PubMed]

26. Mattogno, P.P.; Nasi, D.; Iaccarino, C.; Oretti, G.; Santoro, L.; Romano, A. First Case of Primary Sellar/Suprasellar-Intraventricular Ewing Sarcoma: Case Report and Review of the Literature. *World Neurosurg.* 2017, 98, 869.e1–869.e5. [CrossRef] [PubMed]

27. Grevener, K.; Haveman, L.M.; Ranft, A.; van den Berg, H.; Jung, S.; Ladenstein, R.; Klco-Brosius, S.; Juergens, H.; Merks, J.H.; Dirksen, U. Management and Outcome of Ewing Sarcoma of the Head and Neck. *Pediatr. Blood Cancer* 2016, 63, 604–610. [CrossRef] [PubMed]

28. Kiewe, P.; Neumann, M.; Wagner, T.; Seyfert, S.; Albrecht, H.; Thiel, E.; Korfel, A. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies. *Cancer Chemother. Pharmacol.* 2011, 67, 27–33. [CrossRef]

29. Yule, S.M.; Price, L.; Pearson, A.D.; Boddy, A.V. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. *Clin. Cancer Res.* 1997, 3, 1985–1992.

30. Pitz, M.W.; Desai, A.; Grossman, S.A.; Blakeley, J.O. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. *J. Neurooncol.* 2011, 104, 629–638. [CrossRef]

31. Kiya, K.; Uozumi, T.; Ogasawara, H.; Sugiyama, K.; Hotta, T.; Mikami, T.; Kurisu, K. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. *Cancer Chemother. Pharmacol.* 1992, 29, 339–342. [CrossRef] [PubMed]

32. Rousselle, C.; Smirnova, M.; Clair, P.; Lefauchonnier, J.M.; Chavanieu, A.; Calas, B.; Scherrmann, J.M.; Temsamani, J. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: Saturation kinetics and specificity. *J. Pharmacol. Exp. Ther.* 2001, 296, 124–131. [PubMed]

33. Kellie, S.J.; Barbaric, D.; Koopmans, P.; Earl, J.; Carr, D.J.; de Graaf, S.S. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: A surrogate marker of brain penetration. *Cancer* 2002, 15, 1815–1820. [CrossRef] [PubMed]

34. Cotterill, S.J.; Ahrens, S.; Paulussen, M.; Jürgens, H.F.; Voûte, P.A.; Gadner, H.; Craft, A.W. Prognostic factors in Ewing’s tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. *J. Clin. Oncol.* 2000, 18, 3108–3114. [CrossRef] [PubMed]

35. Mazur, M.A.; Gururangan, S.; Bridge, J.A.; Cummings, T.J.; Mukundan, S.; Fuchs, H.; Larrier, N.; Halperin, E.C. Intracranial Ewing sarcoma. *Pediatr. Blood Cancer* 2005, 45, 850–856. [CrossRef]